NewLink Genetics Corp. (NASDAQ:NLNK) shares rose 2.2% on Friday . The stock traded as high as $11.00 and last traded at $10.92, with a volume of 81,208 shares. The stock had previously closed at $10.69.

NLNK has been the topic of several recent analyst reports. Stifel Nicolaus cut their price objective on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Robert W. Baird initiated coverage on shares of NewLink Genetics Corp. in a report on Tuesday, March 22nd. They set an “outperform” rating and a $27.00 price objective on the stock. Mizuho cut their price objective on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $62.00 price objective on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Finally, SunTrust Banks Inc. lowered shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $59.00 to $12.00 in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. NewLink Genetics Corp. currently has an average rating of “Hold” and a consensus target price of $23.29.

The stock’s 50 day moving average is $11.18 and its 200 day moving average is $18.15. The stock’s market capitalization is $316.89 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its quarterly earnings results on Friday, April 29th. The company reported ($0.82) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.70) by $0.88. The company earned $4.34 million during the quarter, compared to analysts’ expectations of $2.08 million. On average, analysts forecast that NewLink Genetics Corp. will post ($2.83) EPS for the current fiscal year.

A number of large investors have made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock worth $1,765,000 after buying an additional 300 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock worth $1,402,000 after buying an additional 636 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock worth $2,386,000 after buying an additional 3,498 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock worth $1,993,000 after buying an additional 31,375 shares during the last quarter. Finally, EQIS Capital Management raised its stake in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock worth $1,515,000 after buying an additional 35,587 shares during the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.